Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo

An ability to activate latent HIV-1 expression could benefit many HIV cure strategies, but the first generation of latency reversing agents (LRAs) has proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhibitors (GSK-3i's), S...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of virology 2021-03, Vol.95 (8)
Hauptverfasser:	Gramatica, Andrea, Schwarzer, Roland, Brantley, William, Varco-Merth, Benjamin, Sperber, Hannah S, Hull, Philip A, Montano, Mauricio, Migueles, Stephen A, Rosenthal, Danielle, Hogan, Louise E, Johnson, Jeffrey R, Packard, Thomas A, Grimmett, Zachary W, Herzig, Eytan, Besnard, Emilie, Nekorchuk, Michael, Hsiao, Feng, Deeks, Steven G, Snape, Michael, Kiernan, Bernard, Roan, Nadia R, Lifson, Jeffrey D, Estes, Jacob D, Picker, Louis J, Verdin, Eric, Krogan, Nevan J, Henrich, Timothy J, Connors, Mark, Ott, Melanie, Pillai, Satish K, Okoye, Afam A, Greene, Warner C
Format:	Artikel
Sprache:	eng
Schlagworte:	Vaccines and Antiviral Agents
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!